MMC/UFT/LV in refractory colorectal cancer: phase II study and analysis of predictive variables of progression
- 57 Downloads
The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate.
Patients and methods
We conducted a multicentre phase II trial assessing the disease control rate (DCR) of the combination of tegafur/uracil and mitomycin C in rmCRC. The number of previous lines of chemotherapy, carcinoembryonic antigen (CEA) levels, progression-free survival of the last chemotherapy regimen (PPFS), and the neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio at the time of study entry were evaluated as indicators of early progression.
We enrolled 42 patients. The combination was well tolerated with a DCR of 26.2% and median overall survival of 6.9 months. Low CEA levels, PPFS >6 months and low NLR were significantly associated with better prognosis.
The study failed its primary endpoint. However, some putative indicators of early progressive patients have been described.
KeywordsColorectal cancer Mitomycin C UFT Predictive markers
Compliance with ethical standards
Conflict of interest
The authors declare no potential conflict of interest.
- 3.Hoff PM, Pazdur R, Benner SE, Canetta R (1998) UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer 9(6):479–490Google Scholar
- 13.Neofytou K, Smyth EC, Giakoustidis A et al (2014) Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol 31(10):239CrossRefPubMedGoogle Scholar
- 14.Kodaira S (1997) Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer. Oncology (Williston Park) 11(9 Suppl 10):40–43Google Scholar